25
Participants
Start Date
October 21, 2020
Primary Completion Date
June 5, 2024
Study Completion Date
June 21, 2024
lerapolturev
Lerapolturev (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
pembrolizumab
Pembrolizumab (200 mg IV) given every 3 weeks.
Duke University Medical Center, Durham
Baptist MD Anderson Cancer Center, Jacksonville
The Ohio State University, Columbus
University Hospitals Cleveland Medical Center, Cleveland
University of California San Francisco, San Francisco
Oregon Health and Science University, Portland
UConn Health, Farmington
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Lead Sponsor
Istari Oncology, Inc.
INDUSTRY